Skip to content

DNA on Demand: What Pharmacists Need to Know about Direct-to-Consumer Pharmacogenomic Testing

Pharmacogenomics addresses how individuals’ genes influence drug response and genetic testing is used by clinicians to maximize drug efficacy. However, DNA tests sold to consumers without the involvement of healthcare professionals (Direct-to-Consumer, or DTC) are widely available online and over-the-counter at pharmacies. Patients and providers may turn to pharmacists for pharmacogenomics information, and pharmacists should be equipped with baseline knowledge in this area. This module introduces pharmacists to clinically significant and valid information that can be learned from these tests, the regulatory landscape of DTC genomic testing, and covers information resources available to practitioners.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Identify the benefits and limitations of direct-to-consumer (DTC) pharmacogenomic testing.
  • Describe freely-available, evidence-based resources for evaluating the clinical implications of DTC pharmacogenomic test results.
  • Review key considerations for counseling patients about DTC pharmacogenomic testing.


Roseann S. Gammal, PharmD, BCPS is an Assistant Professor of Pharmacy Practice at MCPHS University in Boston, MA. She received her Bachelor of Science degrees in Chemistry and Biochemistry from Worcester Polytechnic Institute and her Doctor of Pharmacy degree from MCPHS University in Worcester, MA. She completed a PGY1 Pharmacy Practice residency at the University of North Carolina Medical Center in Chapel Hill, NC and a PGY2 specialty residency in Clinical Pharmacogenetics at St. Jude Children’s Research Hospital in Memphis, TN. Dr. Gammal is a Board Certified Pharmacotherapy Specialist and a nationally recognized expert in the field of pharmacogenomics. She has recently served as Chair of both the American College of Clinical Pharmacy’s Pharmacokinetics/Pharmacodynamics/Pharmacogenomics Practice and Research Network and the American Association of Colleges of Pharmacy’s Pharmacogenomics Special Interest Group. In addition, she works with the NIH-funded Clinical Pharmacogenetics Implementation Consortium to create evidence-based clinical practice guidelines that describe how to use pharmacogenomic test results to optimize medication therapy. Dr. Gammal is also the co-founder and lead clinical pharmacist for the Pharmacogenomics Clinic at Brigham and Women’s Hospital in Boston.

Free for MCPHS alumni, faculty and staff. For all others the fee is $12.00


ACPE logo

Release Date: 3/25/21
Expiration Date: 3/23/2023
Contact Hours: 1.0
Universal Activity Number: 0026-0000-21-124-H04-P
Topic Designator: General

MCPHS offers a Graduate Certificate in Precision Medicine through the School of Professional Studies.


MCPHS University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (.10 CEUs).

Requirements for Credit

In order to receive credit, the participant must review the entire presentation and complete the post-test and evaluation form. Upon completion participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

MCPHS University adheres to the ACPE Standards regarding commercial support of continuing pharmacy education. It is the policy of MCPHS University that the speakers and planning committee disclose real or apparent conflicts of interest relating to the topics of the educational activity, that relevant conflicts of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.

No funding from industry provided for this event. No exhibitors will be present.
Roseann S. Gammal, PharmD, BCPS, has no relevant financial relationships to disclose.
All CE staff members have no relevant financial relationships to disclose.